Sexual Health Market Value to Worth Over US$ 14.1 Billion at 4.2% CAGR Growth Rate | Technology Snapshot with Solution to Drive Market Growth by 2027
Global Sexual Health Market, by Product Type (Erectile Dysfunction Drugs, Gender Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs, Premature Ejaculation Drugs, and Others), by Gender (Male and Female), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 10,289.5 million in 2019 and is expected to exhibit a CAGR of 4.2%, over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3364
Key players in the pharmaceutical industry are focusing on launching several drugs for treating sexual dysfunction, and this is expected to drive growth of the sexual health market over the forecast period. For instance, in 2017, Teva Pharmaceutical Industries Ltd. launched generic version of Viagra (sildenafil citrate) tablets in the U.S. that is indicated for the treatment of erectile dysfunction. Similarly, in September 2019, Lupin Limited launched Sildenafil tablets, a generic version of Pfizer Inc.’s Viagra tablets in the U.S. indicated for the treatment of erectile dysfunction.
The sexual health market is expected to exhibit significant growth over the forecast period, attributed to rising initiatives by major players operating in the market. These players are focusing on adopting inorganic growth strategies such as collaborations and partnerships to distribute their product, globally and to expand their consumer base. For instance, in May 2014, Sanofi entered an acquisition agreement with Eli Lilly and Company to acquire the rights from the Eli Lilly and Company to apply for regulatory approval for the nonprescription Cialis (OTC) in the U.S., Europe, Canada and Australia.
Moreover, increasing number of approval of drugs from regulatory bodies for improving sexual health is expected to drive the global sexual health market growth over the forecast period. For instance, VIVUS, Inc., a biopharmaceutical company, received approval from the Ministry of Health of the Russian Federation for its Avanafil tablet (with strength of 50 mg, 100 mg and 200 mg tablets) for treatment of erectile dysfunction (ED), in March 2019. The product is also approved in Jordan, Saudi Arabia, Turkey, and the United Arab Emirates market.
Browse 35 Market Data Tables and 31 Figures spread through 167 Pages and in-depth TOC on ‘Global Sexual Health Market, by Product Type (Erectile Dysfunction Drugs, Gender Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs, Premature Ejaculation Drugs, and Others), by Gender (Male, and Female), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),, and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2027’
To know the latest trends and insights related to Global Sexual Health Market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/sexual-health-market-2728
Key Takeaways of the Global Sexual Health Market:
- The global sexual health market is expected to exhibit a CAGR of 4.2% over the forecast period (2019-2027) attributed to increasing drug launches for the treatment of sexual dysfunction. For instance, in June 2019, Novitium Pharma LLC received the U.S. FDA approval for its Sildenafil for Oral Suspension, 10mg/mL, (a generic of Pfizer’s Revatio).
- Moreover, increasing clinical trials by key players for developing novel treatment option for treating sexual dysfunctions is expected to drive the global sexual health market growth over the forecast period. For instance, in July 31, 2019, Futura Medical Developments Ltd. initiated phase 3 clinical trial to demonstrate the efficacy of various doses of MED2005 (Glyceryl Trinitrate (GTN)) for the treatment of erectile dysfunction, and to evaluate the long-term efficacy and safety (12 months) of MED2005. The study is estimated to complete in October 1, 2020.
- Key players operating in the global sexual health market include Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus Pharmaceuticals, IVFTECH APS, Merck & Co., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis International AG, Mylan Pharmaceuticals Inc., and AstraZeneca.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire